1. European Medicines Agency. Draft guideline on the risk-based approach according toAnnex I, part IV of Directive 2001/83/EC applied to Advanced Therapy Medicinal Products: EMA/CAT/CPWP/686637/2011; January, 19. 30 Churchill Place, Canary Wharf, London E14 5EU, United Kingdom: European Medicines Agency (EMA). http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2013/03/WC500139748.pdf .
2. Guideline on Safety and Efficacy Follow-up - Risk Management of Advanced Therapy Medicinal Products. 2008. European Medicines Agency (EMA). http://www.ema.europa.eu/docs/en_GB/document_library/Regulatory_and_procedural_guideline/2009/10/WC500006326.pdf .
3. Erben RG, Silva-Lima B, Reischl I, Steinhoff G, Tiedemann G, Dalemans W, et al. White paper on how to go forward with cell-based advanced therapies in Europe. Tissue Eng Part A. 2014;20:2549–54.
4. Fickert S, Gerwien P, Helmert B, Schattenberg T, Weckbach S, Kaszkin-Bettag M, et al. One-Year Clinical and Radiological Results of a Prospective, Investigator-Initiated Trial Examining a Novel, Purely Autologous 3-Dimensional Autologous Chondrocyte Transplantation Product in the Knee. Cartilage. 2012;3:27–42.
5. Schubert T, Anders S, Neumann E, Schölmerich J, Hofstädter F, Grifka J, et al. Long-term effects of chondrospheres on cartilage lesions in an autologous chondrocyte implantation model as investigated in the SCID mouse model. Int J Mol Med. 2009;23:455–60.